"Analysis.group","Analysis.number","Analysis.name","Subgroup","Applicability","Study","Study.year","GIV.Mean","GIV.SE","Experimental.mean","Experimental.SD","Experimental.cases","Experimental.N","Control.mean","Control.SD","Control.cases","Control.N","O.E","Variance","Weight","Mean","CI.start","CI.end","Footnotes","review.url","review.doi","analysis_key","dataset_name","mismatch_type","direction_match","or_sig","rd_sig","log_or","rd","log_or_ci_lb","log_or_ci_ub","rd_ci_lb","rd_ci_ub","sparse_events","double_zero"
1,5,"Continuous abstinence, longest follow-up","CBT","SUBGROUP_AND_OVERALL","Higgins 2003",2003,0,0,0,0,38,45,0,0,29,40,0,0,58.942989,1.164751,0.926943,1.463568,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011866.pub3/full","10.1002/14651858.CD011866.pub3","5::overall","CD011866_pub3_data","significance_only",TRUE,FALSE,TRUE,0.55804630332189,0.141009493705331,-0.0573565405791392,1.17344914722292,0.0141174988144964,0.267901488596165,TRUE,TRUE
1,5,"Continuous abstinence, longest follow-up","Contingency management","SUBGROUP_AND_OVERALL","Higgins 1994",1994,0,0,0,0,6,20,0,0,1,20,0,0,2.127397,6,0.792564,45.422227,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011866.pub3/full","10.1002/14651858.CD011866.pub3","5::overall","CD011866_pub3_data","significance_only",TRUE,FALSE,TRUE,0.55804630332189,0.141009493705331,-0.0573565405791392,1.17344914722292,0.0141174988144964,0.267901488596165,TRUE,TRUE
1,5,"Continuous abstinence, longest follow-up","Contingency management","SUBGROUP_AND_OVERALL","Petry 2018",2018,0,0,0,0,37,80,0,0,28,61,0,0,38.929615,1.007589,0.702557,1.44506,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011866.pub3/full","10.1002/14651858.CD011866.pub3","5::overall","CD011866_pub3_data","significance_only",TRUE,FALSE,TRUE,0.55804630332189,0.141009493705331,-0.0573565405791392,1.17344914722292,0.0141174988144964,0.267901488596165,TRUE,TRUE
2,5,"Frequency of drug intake, end of treatment","Motivational interviewing","SUBGROUP_AND_OVERALL","Sorsdahl 2021",2021,0,0,4.83,7.86,0,17,6.43,4.62,0,22,0,0,24.708143,-0.251526,-0.887172,0.38412,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011866.pub3/full","10.1002/14651858.CD011866.pub3","5::overall","CD011866_pub3_data","significance_only",TRUE,FALSE,TRUE,0.55804630332189,0.141009493705331,-0.0573565405791392,1.17344914722292,0.0141174988144964,0.267901488596165,TRUE,TRUE
2,5,"Frequency of drug intake, end of treatment","Motivational interviewing + CBT","SUBGROUP_AND_OVERALL","Parsons 2018",2018,0,0,2.21,4.49,0,105,1.93,3.18,0,105,0,0,25.483453,0.07171,-0.19888,0.342299,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011866.pub3/full","10.1002/14651858.CD011866.pub3","5::overall","CD011866_pub3_data","significance_only",TRUE,FALSE,TRUE,0.55804630332189,0.141009493705331,-0.0573565405791392,1.17344914722292,0.0141174988144964,0.267901488596165,TRUE,TRUE
2,5,"Frequency of drug intake, end of treatment","Interpersonal therapy","SUBGROUP_AND_OVERALL","Carroll 1991",1991,0,0,0.27,0.19,0,58,0.24,0.2,0,52,0,0,25.321788,0.152943,-0.22193,0.527816,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011866.pub3/full","10.1002/14651858.CD011866.pub3","5::overall","CD011866_pub3_data","significance_only",TRUE,FALSE,TRUE,0.55804630332189,0.141009493705331,-0.0573565405791392,1.17344914722292,0.0141174988144964,0.267901488596165,TRUE,TRUE
2,5,"Frequency of drug intake, end of treatment","CBT","SUBGROUP_AND_OVERALL","Alammehrjerdi 2019",2019,0,0,5.2,3.77,0,60,18.8,1.39,0,60,0,0,24.486615,-4.756197,-5.465013,-4.047381,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011866.pub3/full","10.1002/14651858.CD011866.pub3","5::overall","CD011866_pub3_data","significance_only",TRUE,FALSE,TRUE,0.55804630332189,0.141009493705331,-0.0573565405791392,1.17344914722292,0.0141174988144964,0.267901488596165,TRUE,TRUE
3,5,"Severity of dependence","","SUBGROUP_AND_OVERALL","Higgins 2000",2000,0,0,0.14,0.06,0,36,0.13,0.06,0,34,0,0,100,0.164822,-0.304733,0.634376,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011866.pub3/full","10.1002/14651858.CD011866.pub3","5::overall","CD011866_pub3_data","significance_only",TRUE,FALSE,TRUE,0.55804630332189,0.141009493705331,-0.0573565405791392,1.17344914722292,0.0141174988144964,0.267901488596165,TRUE,TRUE
4,5,"Continuous abstinence, longest follow-up","12-step facilitation","SUBGROUP_AND_OVERALL","Carroll 1998",1998,0,0,0,0,14,24,0,0,8,27,0,0,100,1.96875,1.004927,3.856975,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011866.pub3/full","10.1002/14651858.CD011866.pub3","5::overall","CD011866_pub3_data","significance_only",TRUE,FALSE,TRUE,0.55804630332189,0.141009493705331,-0.0573565405791392,1.17344914722292,0.0141174988144964,0.267901488596165,TRUE,TRUE
